BIOR Biora Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIOR

Price (delayed)

$0.731

Market cap

$22.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.87

Enterprise value

$52.66M

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. ...

Highlights
Biora Therapeutics's debt has shrunk by 64% YoY and by 43% QoQ
The equity is up by 15% since the previous quarter
BIOR's quick ratio has dropped by 82% year-on-year but it is up by 33% since the previous quarter
The EPS has plunged by 57% YoY but it has grown by 18% from the previous quarter
The revenue has plunged by 99% YoY and by 78% from the previous quarter
BIOR's gross profit has shrunk by 99% YoY and by 78% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.progenity.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BIOR
Market
Shares outstanding
30.31M
Market cap
$22.16M
Enterprise value
$52.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2,882.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13,165.03
Earnings
Revenue
$4,000
EBIT
-$114.39M
EBITDA
-$113.84M
Free cash flow
-$48.59M
Per share
EPS
-$7.87
Free cash flow per share
-$3.08
Book value per share
-$4.28
Revenue per share
$0
TBVPS
$1.59
Balance sheet
Total assets
$31.22M
Total liabilities
$132.64M
Debt
$45.71M
Equity
-$101.42M
Working capital
-$43.9M
Liquidity
Debt to equity
-0.45
Current ratio
0.3
Quick ratio
0.24
Net debt/EBITDA
-0.27
Margins
EBITDA margin
-2.85M%
Gross margin
100%
Net margin
-3.1M%
Operating margin
-1.68M%
Efficiency
Return on assets
-294.1%
Return on equity
N/A
Return on invested capital
-184.9%
Return on capital employed
N/A
Return on sales
-2.86M%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOR stock price

How has the Biora Therapeutics stock price performed over time
Intraday
2.96%
1 week
16.03%
1 month
-1.22%
1 year
-68.76%
YTD
-45.85%
QTD
-33.55%

Financial performance

How have Biora Therapeutics's revenue and profit performed over time
Revenue
$4,000
Gross profit
$4,000
Operating income
-$67.14M
Net income
-$124.12M
Gross margin
100%
Net margin
-3.1M%
The revenue has plunged by 99% YoY and by 78% from the previous quarter
BIOR's gross profit has shrunk by 99% YoY and by 78% QoQ
BIOR's operating income is down by 9% YoY

Growth

What is Biora Therapeutics's growth rate over time

Valuation

What is Biora Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2,882.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13,165.03
The EPS has plunged by 57% YoY but it has grown by 18% from the previous quarter
The equity is up by 15% since the previous quarter
The revenue has plunged by 99% YoY and by 78% from the previous quarter
The P/S is 49% higher than the last 4 quarters average of 1940.9

Efficiency

How efficient is Biora Therapeutics business performance
The company's return on invested capital has shrunk by 56% QoQ
The return on assets has declined by 15% since the previous quarter

Dividends

What is BIOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOR.

Financial health

How did Biora Therapeutics financials performed over time
Biora Therapeutics's total assets is 76% less than its total liabilities
BIOR's quick ratio has dropped by 82% year-on-year but it is up by 33% since the previous quarter
The company's current ratio has shrunk by 82% YoY but it rose by 7% QoQ
Biora Therapeutics's debt is 145% higher than its equity
The debt to equity has surged by 64% year-on-year and by 34% since the previous quarter
Biora Therapeutics's debt has shrunk by 64% YoY and by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.